Jun. 28 at 6:31 PM
$STIM
Here’s a clear breakdown on Greenbrook TMS before the acquisition:
• Revenue: Greenbrook generated approximately
$74 million in 2023. On a pro forma basis with Neuronetics, the combined revenue for 2023 would have been around
$145 million.
• Number of clinics: At the time of the deal announcement in 2024, Greenbrook operated roughly 130 clinics, though this had come down from a peak of nearly 200 after they closed many locations during restructuring. After the acquisition, Neuronetics integrated about 93–95 of those centers.
• Revenue projections over time: Greenbrook had been growing revenue steadily — from about
$52 million in 2021 to
$67 million in 2022 and
$74 million in 2023. The combined company projected mid-teens percentage growth (around 13–17%) for both 2025 and 2026 after the deal closed.
The acquisition basically turned Neuronetics from a device seller into a company that also directly runs a large network of treatment centers.
